GlassScriptPhysician profile
Grantley Ittera
NPI 1619223666
$10,782.85
in general payments reported to CMS, 2019-2025
22 companies · $3,702 in 2025
The $3,702 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,408 · 2024: $3,672 · 2025: $3,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,612.23 |
| Education | $170.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,048.71 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,503.88 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,252.95 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,224.38 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,183.83 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $872.61 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $644.16 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $590.35 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $571.56 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $284.47 | 2025 | Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $203.18 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $106.27 | 2023-2025 | Trintellix |
| Bausch Health US, LLC | $63.80 | 2024-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $50.38 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.00 | 2025 | Abilify Maintena |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $34.18 | 2024-2025 | Xelstrym |
| Bioxcel Therapeutics, INC. | $24.52 | 2024 | Igalmi |
| Tris Pharma INC | $22.84 | 2025 | Dyanavel Xr |
| Lundbeck LLC | $20.89 | 2025 | Rexulti |
| Luye Pharma (USA) LTD. | $17.98 | 2025 | Erzofri Extended-Release |
| Corium, LLC | $17.17 | 2025 | Azstarys |
| Janssen Scientific Affairs, LLC | $8.74 | 2024 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grantley Ittera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.